Candriam Luxembourg S.C.A. reduced its position in Intra-Cellular Therapies Inc. (NASDAQ:ITCI) by 19.3% during the second quarter, Holdings Channel reports. The institutional investor owned 155,000 shares of the biopharmaceutical company’s stock after selling 37,000 shares during the period. Candriam Luxembourg S.C.A.’s holdings in Intra-Cellular Therapies were worth $1,925,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. Bank of America Corp DE increased its stake in Intra-Cellular Therapies by 53.4% in the first quarter. Bank of America Corp DE now owns 9,660 shares of the biopharmaceutical company’s stock worth $157,000 after buying an additional 3,363 shares in the last quarter. Nine Chapters Capital Management LLC purchased a new stake in Intra-Cellular Therapies during the first quarter worth approximately $166,000. Highbridge Capital Management LLC purchased a new stake in Intra-Cellular Therapies during the fourth quarter worth approximately $166,000. Driehaus Capital Management LLC purchased a new stake in Intra-Cellular Therapies during the first quarter worth approximately $292,000. Finally, American International Group Inc. increased its stake in Intra-Cellular Therapies by 7.1% in the first quarter. American International Group Inc. now owns 21,130 shares of the biopharmaceutical company’s stock worth $343,000 after buying an additional 1,396 shares in the last quarter. Institutional investors own 66.60% of the company’s stock.

Shares of Intra-Cellular Therapies Inc. (ITCI) opened at 10.77 on Friday. Intra-Cellular Therapies Inc. has a 52 week low of $7.85 and a 52 week high of $45.20. The company’s market capitalization is $467.63 million. The firm’s 50-day moving average price is $11.98 and its 200 day moving average price is $12.57.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.74) by $0.33. Intra-Cellular Therapies had a negative net margin of 32,834.94% and a negative return on equity of 27.25%. The business had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.03 million. During the same period last year, the company posted ($0.71) EPS. The business’s revenue was down 52.2% on a year-over-year basis. Equities analysts predict that Intra-Cellular Therapies Inc. will post ($2.68) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Intra-Cellular Therapies Inc. (ITCI) Shares Sold by Candriam Luxembourg S.C.A.” was reported by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.dailypolitical.com/2017/08/11/intra-cellular-therapies-inc-itci-shares-sold-by-candriam-luxembourg-s-c-a.html.

A number of research firms recently commented on ITCI. BidaskClub downgraded Intra-Cellular Therapies from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. Piper Jaffray Companies set a $10.00 target price on Intra-Cellular Therapies and gave the stock a “hold” rating in a research report on Thursday. Cantor Fitzgerald reiterated a “buy” rating on shares of Intra-Cellular Therapies in a research report on Wednesday. Zacks Investment Research upgraded Intra-Cellular Therapies from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a research report on Tuesday, May 16th. Finally, Leerink Swann downgraded Intra-Cellular Therapies from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $29.00 to $10.00 in a research report on Tuesday, May 2nd. Two research analysts have rated the stock with a sell rating, five have given a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $24.14.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).

Want to see what other hedge funds are holding ITCI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intra-Cellular Therapies Inc. (NASDAQ:ITCI).

Institutional Ownership by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.